potassiumiin

Potassiumiin is a pharmaceutical product marketed primarily in Finland and neighboring Nordic countries as a supplement to increase serum potassium levels. The product is available in both drink and tablet formulations, with each tablet containing approximately 10 mmol of elemental potassium. It is intended for use in patients with mild to moderate hypokalemia, including those on diuretic therapy or suffering from chronic kidney disease, as well as for individuals recovering from acute electrolyte imbalances.

The active ingredient is potassium chloride, a commonly used salt in clinical practice to restore potassium homeostasis. Dosage regimens are tailored to individual needs, typically ranging from 1 to 3 tablets per day, but patients are advised to follow a physician’s recommendation. Potassiumiin is marketed in a low-sodium form to minimize additional salt intake. In some countries, the drink variant is prescribed to children or patients who have difficulty swallowing tablets, with a measured volume delivering the same elemental potassium dose.

Common adverse effects reported in clinical studies include gastrointestinal discomfort, nausea, and mild constipation. Rare cases of hyperkalemia have been observed in patients with impaired renal function or those receiving other potassium‑sparing medications. The product is approved by the Swissmedic and the Finnish Medicines Agency (Fimea) for the above indications, and is sold over the counter in pharmacies under a tight regulatory framework that requires patient education on correct use and monitoring of serum potassium levels.